Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma; Plasmacytoma
  • Focus Registrational; Therapeutic Use
  • Acronyms POLLUX
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 31 May 2020 Results (n=3070) of meta-analysis of 6 studies (ALCYCONE, MAIA, CASSIOPEIA, CASTOR, POLLUX & CANDOR) assessing efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
    • 20 Feb 2020 PK analysis results of splitting the first daratumumab IV dose into two separate infusions published in the Advances in Therapy
    • 10 Dec 2019 Results comparing the cost per progression-free survival (PFS) for each of the comparators from the perspective of the Brazilian private healthcare system using PFS values based on POLLUX, ASPIRE, TOURMALINE MM1 and ENDEAVOR trials presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top